Abstract | AIMS: METHODS: Independent hHF/CV death risk factors were determined using Cox proportional hazards models, with participants censored at first hHF event, CV death, or end of follow-up. RESULTS: During median 5-year follow-up, the composite outcome of hHF/CV death occurred in 393 (6.0%) participants. Significant hHF/CV death multivariate predictors were higher age and plasma creatinine, and prior heart failure (HF), myocardial infarction (MI), atrial fibrillation (AF) and stroke. Acarbose, compared with placebo, did not reduce hHF/CV death (hazard ratio [HR] 0.89, 95% CI 0.64-1.24, P = 0.48) or hHF (HR 0.90, 95% CI 0.74-1.10, P = 0.32). CONCLUSIONS: Patients with CHD and IGT at greater risk of hHF/CV death were older with higher plasma creatinine, prior HF, MI, AF or stroke. Addition of acarbose to optimised CV therapy to reduce post-prandial glucose excursions did not reduce the risk of hHF/CV death or hHF. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, number NCT00829660, and the International Standard Randomised Controlled Trial Number registry, number ISRCTN91899513.
|
Authors | Malgorzata Wamil, John J V McMurray, Charles A B Scott, Ruth L Coleman, Yihong Sun, Eberhard Standl, Lars Rydén, Rury R Holman |
Journal | Diabetes research and clinical practice
(Diabetes Res Clin Pract)
Vol. 170
Pg. 108488
(Dec 2020)
ISSN: 1872-8227 [Electronic] Ireland |
PMID | 33035598
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2020 Elsevier B.V. All rights reserved. |
Chemical References |
- Glycoside Hydrolase Inhibitors
- Creatinine
- Acarbose
|
Topics |
- Acarbose
(therapeutic use)
- Aged
- Coronary Disease
(epidemiology, mortality)
- Creatinine
(blood)
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Double-Blind Method
- Female
- Glucose Intolerance
(epidemiology)
- Glycoside Hydrolase Inhibitors
(therapeutic use)
- Heart Failure
(epidemiology, mortality)
- Humans
- Incidence
- Male
- Middle Aged
- Myocardial Infarction
(epidemiology, mortality)
- Proportional Hazards Models
- Risk Factors
- Treatment Outcome
|